论文部分内容阅读
目的：了解哮喘患者吸入皮质激素治疗前后血小板膜糖蛋白（ＧＰ）及血浆血栓素Ｂ２（ＴＸＢ２）、６－酮前列腺素Ｆ１α（６－Ｋ－ＰＧＦ１α）等项指标的变化，并分析它们在哮喘发病中可能的临床意义。方法：用流式细胞术（ＦＣＭ）测哮喘患者血小板膜ＧＰⅠｂ、ＧＰⅠｂ／Ⅸ、ＧＰⅡｂ／Ⅲａ和ＧＰＭ－１４０并用放免法测血浆ＴＸＢ２、６－Ｋ－ＰＧＦ１α。结果：①哮喘患者治疗前四种血小板膜ＧＰⅠｂ、ＧＰⅠｂ／Ⅸ、ＧＰⅡｂ／Ⅲａ、ＧＭＰ－１４０和ＴＸＢ２表达明显增高（Ｐ＜０．０５），６－Ｋ－ＰＧＦ１α比正常对照组显著降低（Ｐ＜０．０５）。②治疗后ＧＰⅠｂ、ＧＰⅡｂ／Ⅲａ和ＧＭＰ－１４０及ＴＸＢ２、６－Ｋ－ＰＧＦ１α有显著改善（Ｐ＜０．０５）。③多元逐步回归分析结果提示：ＧＰ的变化与ＴＸＢ２的变化呈显著正相关（Ｐ＜０．００１），与６－Ｋ－ＰＧＦ１α的变化呈显著负相关（Ｐ＜０．００１）。④吸入激素治疗后，ＦＥＶ１明显改善。结论：①ＧＰ可作为血小板活化的特异性指标。②ＧＰ不仅通过介导血小板粘附聚集参与血小板活化，而且还通过对血小板活化后释放的花生四烯酸（ＡＡ）代谢产物的影响，参与哮喘发病。③吸入糖皮质激素是治疗哮喘的有效药物。
Objective: To understand the changes of platelet membrane glycoprotein (GP), plasma TXB2 and 6-K-PGF1α before and after inhaled corticosteroids treatment in asthmatic patients and to analyze their changes in asthma The possible clinical significance of the disease. Methods: Platelet membrane GPⅠb, GPⅠb / Ⅸ, GPⅡb / Ⅲa and GPM-140 in asthmatic patients were determined by flow cytometry (FCM). Plasma TXB2,6-K-PGF1α was detected by radioimmunoassay. Results: (1) The expression of GPⅠb, GPⅠb / Ⅸ, GPⅡb / Ⅲa, GMP-140 and TXB2 in the four platelets of patients with asthma before and after treatment were significantly higher than those in normal controls (P <0.05) <0.05). ② After treatment, GPⅠb, GPⅡb / Ⅲa, GMP-140 and TXB2, 6-K-PGF1α were significantly improved (P <0.05). ③ The results of multivariate stepwise regression analysis showed that the changes of GP were positively correlated with the changes of TXB2 (P <0.001), and negatively correlated with the changes of 6-K-PGF1α (P <0.001). ④ inhaled hormone therapy, FEV1 significantly improved. Conclusion: GP can be used as a specific indicator of platelet activation. ② GP not only participates in platelet activation by mediating platelet adhesion and aggregation, but also participates in the pathogenesis of asthma through the influence of arachidonic acid (AA) metabolites released after platelet activation. ③ inhaled corticosteroids are effective drugs for the treatment of asthma.